In the last decade, observational studies have been officially established as the methodology for influenza vaccine effectiveness (IVE) estimations in the hope they could improve the external validity of the trial evidence. But they are markedly subject to bias and their IVE estimates have limited public health significance due to their low-certainty evidence. Discrepancies among IVE estimations weaken influenza vaccine confidence leading to undesirable low coverages. In this regard, we purpose to implement the commonly used methodologies (Standard case-control, TND, cohort and cohort-nested TND) and other new (computational modelling) to estimate IVE and CVE using data from the same study population, during the same seasons (2011-2022 for Influenza and 2021-2022 for COVID-19) and from both GP (General Practitioner)/hospital sentinel networks and Real-World Data (RWD). Our aim is to compare variability, robustness and reliability among them and providing the required information to standardize protocols for surveillance of vaccine effectiveness (VE). This project offers the unique scenario to develop for the first time an exhaustive and necessary scrutiny of the different methodologies for the reliable estimation of VE for public health decision-making.
Efectividad vacunal
gripe
COVID-19
salud pública
políticas en salud
Acción Estratégica en Salud (AES)
01/01/2022 - 31/12/2024
ALEJANDRO, ORRICO SANCHEZ
FUNDACION PARA EL FOMENTO DE LA INV. SANITARIA Y BIOMEDICA DE LA COMUNIDAD VALENCIANA (FISABIO)
FISABIO SALUD PUBLICA
COM. VALENCIANA
VALENCIA/VALÈNCIA
32,000 €